Veradermics, Incorporated (MANE)
Healthcare • Biotechnology
StockNYSEUnited StatesUS9229671048
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Veradermics, Incorporated, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 14:06. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 13 Aug 2026 08:00 | -0.64 | — | — | — |
| 30 Mar 2026 17:00 | -18.24 | -104.54 | -473.1% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -70M | — | -2.38 | -73.3% | -71.6M |
| 2024 | 0 | — | -26.5M | — | -1.37 | +9.2% | -23.7M |
| 2023 | 0 | — | -16.5M | — | -1.51 | — | -13.5M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 146.66 | 147.54 | 133.92 | 135.29 | -13.59% | 2,304,800 | |
| 11 Nov 2026 | 148.74 | 156.63 | 146.73 | 156.56 | +5.47% | 706,900 | |
| 10 Nov 2026 | 141.81 | 152.82 | 141.81 | 148.44 | +3.12% | 599,200 | |
| 09 Nov 2026 | 138.06 | 145.48 | 131.38 | 143.95 | +3.73% | 492,100 | |
| 06 Nov 2026 | 130.93 | 139.89 | 130.00 | 138.78 | +7.92% | 503,200 | |
| 05 Nov 2026 | 136.20 | 136.50 | 125.34 | 128.60 | -5.79% | 788,100 | |
| 04 Nov 2026 | 136.51 | 138.66 | 130.51 | 136.51 | +2.17% | 562,400 | |
| 03 Nov 2026 | 131.02 | 138.48 | 131.02 | 133.61 | +3.15% | 536,300 | |
| 02 Nov 2026 | 139.00 | 139.72 | 128.94 | 129.53 | -7.27% | 635,600 | |
| 30 Oct 2026 | 141.79 | 145.41 | 138.33 | 139.69 | -2.89% | 464,800 | |
| 186 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Veradermics to Present at the Jefferies Global Healthcare Conference in London (opens in a new tab) 12 Nov 2026 21:30
- Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss - Slideshow (opens in a new tab) SeekingAlpha · 12 Nov 2026 18:54
- Veradermics: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 10 Nov 2026 22:49
- Citigroup Maintains Buy on Veradermics, Raises Price Target to $175 (opens in a new tab) Benzinga · 10 Nov 2026 15:32
- Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (opens in a new tab) 10 Nov 2026 12:30
- Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss Transcript (opens in a new tab) SeekingAlpha · 10 Nov 2026 05:01
- Veradermics stock rises on 12-month hair growth trial data (opens in a new tab) Investing.com · 09 Nov 2026 18:04
- Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $150 (opens in a new tab) Benzinga · 09 Nov 2026 17:53
- Veradermics Eyes Historic FDA First After Strong Hair Loss Pill Trial Results (opens in a new tab) Benzinga · 09 Nov 2026 13:08
- Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss (opens in a new tab) 09 Nov 2026 12:00
- Veradermics Announces Topline Results From Registration-Directed Phase 2/3 Trial Of VDPHL01, Demonstrating Efficacy In Male Pattern Hair Loss (opens in a new tab) Benzinga · 09 Nov 2026 08:20
- Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss (opens in a new tab) 08 Nov 2026 23:00
- Veradermics (MANE) Late Stage Trial Narrative Keeps Undervalued View Alive (opens in a new tab) Simply Wall St. · 06 Nov 2026 15:13
- Why This Hair Restoration Biotech's Shares Are Soaring (opens in a new tab) Motley Fool · 25 Oct 2026 13:20
- Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough (opens in a new tab) Benzinga · 22 Oct 2026 11:24
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 156.56 USD
- Market cap
- 5.7B
- Exchange
- NYSE
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 6.2 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -57.1× | Weak | 14.16× |
| Price / book | -0.91× | Weak | 3.5× |
| Free cash flow yield | -1.2% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 54.9% |
| Operating margin | 0% | Weak | 5.8% |
| Net margin | 0% | Weak | 1.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0× | Good | 0.4× |
| Current ratio | 70.53× | Good | 2.64× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow MANE and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.